Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Recombinant human epidermal growth factor compound enema for prevention and treatment of radiation proctitis after adjuvant radiotherapy for cervical cancer
ChiCTR2000032841Phase 4Recruiting
- Sponsor
- Affiliated Cancer Hospital of Guangzhou Medical University
- Start
- May 2020
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of nepidermin in radiation proctitis (2 arms), sponsored by Affiliated Cancer Hospital of Guangzhou Medical University. Primary endpoints: Incidence of grade 2-4 acute radiation proctitis and Quality of life score (QLQ-C30). Started May 2020; status: recruiting.
02
Drugs
nepidermin
03
Conditions
radiation proctitis
Beyond the preview
Go deeper on ChiCTR2000032841.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2000032841.